Stay updated on Nivolumab vs Placebo in Preventing Melanoma Recurrence Clinical Trial
Sign up to get notified when there's something new on the Nivolumab vs Placebo in Preventing Melanoma Recurrence Clinical Trial page.

Latest updates to the Nivolumab vs Placebo in Preventing Melanoma Recurrence Clinical Trial page
- Check2 days agoChange DetectedThe footer’s ClinicalTrials.gov revision label changed from v3.7.1 to v3.7.2.SummaryDifference0.0%

- Check9 days agoChange DetectedThe footer revision label changed from v3.7.0 to v3.7.1.SummaryDifference0.0%

- Check16 days agoNo Change Detected
- Check30 days agoChange DetectedThe record history now shows a new revision entry (v3.7.0). The previous revision (v3.6.6) is removed, updating the version history of the study record.SummaryDifference0.0%

- Check51 days agoChange DetectedFooter now displays Revision: v3.6.6 on the Record History page, replacing the previous v3.6.5. This appears to be an update to the site version rather than a change to the trial data or visible content.SummaryDifference0.0%

- Check72 days agoChange DetectedVersion 63 introduces labeled sections for Eligibility, Study Status, and Study Identification in the Record History, organizing past changes by study-area for easier navigation.SummaryDifference0.3%

- Check86 days agoChange DetectedA new revision tag v3.6.4 was added to the page history, replacing the previous v3.6.3. This reflects a minor site update to the history page.SummaryDifference0.0%

Stay in the know with updates to Nivolumab vs Placebo in Preventing Melanoma Recurrence Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab vs Placebo in Preventing Melanoma Recurrence Clinical Trial page.